# New Formulations of Propafenone to Treat Atrial Fibrillation

Study · id `cardio:ct-nct02710669` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02710669](<https://clinicaltrials.gov/study/NCT02710669>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02710669

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 193 participants.

## Technical summary

Registry record NCT02710669. Randomized; triple masking; primary purpose treatment. Start 2016-10 (registry gives no type); primary completion 2020-03-11 (actual). Results posted on 2021-05-14.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 193 participants (enrolled count; ClinicalTrials.gov record NCT02710669, source copy `cardio:ctgov-nct02710669-2022-06-03`, retrieved 2026-10-26)
- Start date: 2016-10 (registry gives no type) (ClinicalTrials.gov record NCT02710669, source copy `cardio:ctgov-nct02710669-2022-06-03`, retrieved 2026-10-26)
- Primary completion: 2020-03-11 (actual) (ClinicalTrials.gov record NCT02710669, source copy `cardio:ctgov-nct02710669-2022-06-03`, retrieved 2026-10-26)
- Completion: 2020-04 (actual) (ClinicalTrials.gov record NCT02710669, source copy `cardio:ctgov-nct02710669-2022-06-03`, retrieved 2026-10-26)
- Results first posted: 2021-05-14 (ClinicalTrials.gov record NCT02710669, source copy `cardio:ctgov-nct02710669-2022-06-03`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02710669, source copy `cardio:ctgov-nct02710669-2022-06-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02710669-2022-06-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: New Formulations of Propafenone to Treat Atrial Fibrillation
- Condition: Atrial Fibrillation
- Intervention (Drug): (R)-propafenone
- Intervention (Drug): (S)-Propafenone
- Intervention (Drug): Placebo
- Lead sponsor: Vanderbilt University
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Vanderbilt University (`cardio:org-vanderbilt-university`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A Mechanistic Clinical Trial Using (R)- Versus (S)-Propafenone to Test RyR2 (Ryanodine Receptor) Inhibition for the Prevention of Atrial Fibrillation Induction (`cardio:pubmed-36166682`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 96f9bcdfa2a51b60ff570c6ae9df6b1f65eccce4ffe0efc1cc5b694f9aa9354a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
